Recombinant Human Follicle-Stimulating Hormone Alfa Dose Adjustment in US Clinical Practice: An Observational, Retrospective Analysis of a Real-World Electronic Medical Records Database

To determine the pattern of dose adjustment of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) during ovarian stimulation (OS) for assisted reproductive technology (ART) in a real-world setting. This was an observational, retrospective analysis of data from an electronic de-identif...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in endocrinology (Lausanne) 2021-12, Vol.12, p.742089-742089
Main Authors: Mahony, Mary C, Hayward, Brooke, Mottla, Gilbert L, Richter, Kevin S, Beall, Stephanie, Ball, G David, D'Hooghe, Thomas
Format: Article
Language:English
Subjects:
Adult
Age Factors
assisted reproductive technologies
Body Mass Index
Databases, Factual
dose adjustments
Endocrinology
Female
Follicle Stimulating Hormone, Human - administration & dosage
Follicle Stimulating Hormone, Human - therapeutic use
Humans
infertility
ovarian stimulation
Ovulation Induction
Practice Patterns, Physicians
r-hFSH- alfa
Recombinant Proteins - administration & dosage
Recombinant Proteins - therapeutic use
Reproductive Techniques, Assisted
Retrospective Studies
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To determine the pattern of dose adjustment of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) during ovarian stimulation (OS) for assisted reproductive technology (ART) in a real-world setting. This was an observational, retrospective analysis of data from an electronic de-identified medical records database including 39 clinics in the USA. Women undergoing OS for ART (initiated 2009-2016) with r-hFSH-alfa (Gonal-f or Gonal-f RFF Redi-ject ) were included. Assessed outcomes were patients' baseline characteristics and dosing characteristics/cycle. Of 33,962 ART cycles, 13,823 (40.7%) underwent dose adjustments: 23.4% with ≥1 dose increase, 25.4% with ≥1 dose decrease, and 8.1% with ≥1 increase and ≥1 decrease. Patients who received dose adjustments were younger (mean [SD] age 34.8 [4.58] years versus 35.9 [4.60] years, p
ISSN:1664-2392
1664-2392
DOI:10.3389/fendo.2021.742089